IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Asian Markets Mixed as RBI Cuts Rates and BOJ Signals Possible Hike 
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand 
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
The American mass exodus to Canada amid Trump 2.0 has yet to materialize 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Glastonbury is as popular than ever, but complaints about the lineup reveal its generational challenge 
The pandemic is still disrupting young people’s careers 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Asian Markets Stabilize as Wall Street Rebounds and Rate Concerns Ease 
Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Bubs Australia will manufacture and distribute Bubs’ Chinese-label goat milk infant formula in China according to new Chinese standards. under an agreement with Heilongjiang Ubeite Dairy Group (HUG).
The new standards will come into effect in February 2023 .
The “ultra-premium” infant formula has been specially developed for Chinese infants using easily-digestible A2 goat-milk protein, sn2 palmitate (OPO), lactoferrin prebiotics, and nucleotides.
HUG has started submission with the State Administration for Market Regulation (SAMR) to renew its registration in line with China’s new GB standards for exclusive use under the Bubs brand.
According to Kristy Carr, Bubs founder and CEO, they have built strong brand trust and loyalty with Chinese families through marketing and selling Bubs English label infant formula products via the crossborder eCommerce channel, which accounts for around 20 percent of total Chinese infant formula sales.
If approved by SAMR, the formula will give Bubs access to the remaining 80 percent of China’s $25.9 billion infant formula market.
Bubs will also enter into a joint venture agreement, where it will hold a 75 percent interest, with Zhitong Health Technology to distribute its Chinese label goat infant formula products.
Bubs Australia expects to launch its product in the second half of FY23, subject to receiving SAMR approval.
